Vnitr Lek 2021, 67(8):495-497 | DOI: 10.36290/vnl.2021.126

Expert consensus on the importance of iron deficiency and the possibility of its correction in patients with heart failure

Vojtěch Melenovský1, Miloš Táborský2, Aleš Linhart3, Jan Malík4, Filip Málek5, Radek Pudil6, Jan Krejčí7, Milan Šíranec3
1 Klinika kardiologie IKEM, Praha
2 I. interní klinika, Fakultní nemocnice Olomouc
3 II. interní klinika, Všeobecná fakultní nemocnice, Praha
4 III. interní klinika, Všeobecná fakultní nemocnice, Praha
5 Kardiologické oddělení, Nemocnice na Homolce, Praha
6 I. interní kardioangiologická klinika, Fakultní nemocnice Hradec Králové
7 I. interní kardioangiologická klinika, Fakultní nemocnice u sv. Anny, Brno

Anemia and iron deficiency are common non-cardiovascular comorbidities of heart failure. The prevalence of iron deficiency is up to 55 % of patients with chronic heart failure and up to 80 % subjects with acute heart failure including acute decompensated heart failure, independently on anemia. The European Society of Cardiology Heart Failure Guidelines 2021 recommend intravenous iron replacement in patients with heart failure and iron deficiency to improve symptoms, stress tolerance and quality of life in chronic heart failure and to reduce risk of subsequent hospitalization after acute decompenstation.

Keywords: heart failure, iron deficiency, intravenous replacement.

Published: December 9, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Melenovský V, Táborský M, Linhart A, Malík J, Málek F, Pudil R, et al.. Expert consensus on the importance of iron deficiency and the possibility of its correction in patients with heart failure. Vnitr Lek. 2021;67(8):495-497. doi: 10.36290/vnl.2021.126.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. van der Meer P et al. Mitochondrial Function, Skeletal Muscle Metabolism, and Iron Deficiency in Heart Failure. Circulation. 2019; 139(21): 2399-2402. Go to original source...
    2. Melenovsky V et al. Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis. Eur J Heart Fail. 2017; 19(4): 522-530. Go to original source...
    3. Van der Wal et al. EHJ 2019: 40, 3616-3625.
    4. Lewis GD et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. JAMA. 2017; 317(19): 1958-1966. Go to original source...
    5. SPC Ferinject: https://www.sukl.cz/modules/medication/detail.php?code=0192372 & tab=texts
    6. Anker SD et al. FAIR‑HF Trial: Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009; 361(25): 2436-2448. Go to original source... Go to PubMed...
    7. Ponikowski P et al. CONFIRM‑HF Trial: Beneficial effects of long‑term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015 Mar 14; 36(11): 657-668. Go to original source... Go to PubMed...
    8. Ponikowski P et al. AFFIRM‑AHF Trial: Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double‑blind, randomised, controlled trial. Lancet. 2020; 396(10266): 1895-1904. Go to original source...
    9. Khan MS et al. Ferric carboxymaltose for the treatment of iron‑deficient heart failure patients: a systematic review and meta‑analysis. ESC Heart Fail. 2020; 7(6): 3392-3400. Go to original source...
    10. Ponikowski P et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016; 37(27): 2129-2200. Go to original source... Go to PubMed...
    11. McDonagh TA et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 doi: 10.1093/eurheartj/ehab368. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.